Natco Pharma

News from other websites on Natco Pharma

Japan's Eisai to launch breast cancer drug in India

Nov 06, 2013 at 07:17 | Source: Economic Times

MUMBAI: Japan's Eisai Pharma, a 741 billion yen ( Rs 46,439-crore) pharma major, is slated to launch in India its novel anti-cancer drug Eribulin, sold under the brand name of Halaven, as part of its strategy to expand its presence in the emerging ma...

Elections no worry; Nifty could head towards 8,000 next year: Ashwani Gujral

Nov 02, 2013 at 16:07 | Source: Economic Times

In an interview with ET Now, Ashwani Gujral, Fund Manager, Ashwanigujral.com, shares his views on the market and some stocks. Excerpts: ET Now: How do you see the Nifty given the fact that we are already close to 11% up from the last Diwali to now? ...

Patent office rejects BDR Pharma s compulsory licensing application

Oct 31, 2013 at 16:42 | Source: Economic Times

MUMBAI: The Patent Office rejected the compulsory licensing application of Mumbai-based BDR Pharmaceuticals to make a generic version of US drug maker Bristol-Myers Squibb's anticancer drug Dasatinib, sold under the brand name Sprycel. The ruling co...

BDR's compulsory licence bid for cancer drug rejected: What it means

Oct 31, 2013 at 14:59 | Source: FirstPost

The Indian Patent Office has rejected Mumbai-based BDR Pharmaceuticals'application for a compulsory licence to make a generic version of US drug maker Bristol-Myers Squibb's anti-cancer drug Dasatinib, said media reports today. The development comes ...

BDR Pharma’s application for cheaper cancer drug rejected

Oct 30, 2013 at 23:37 | Source: The Hindu BusinessLine

The Patent Controller has rejected an application from local drug company BDR Pharmaceuticals International Pvt Ltd, seeking a compulsory licence (CL) for its less-expensive version of dasatinib, a cancer drug from multinational Bristol-Myers Squibb...

Fishing for stocks? Go with the FIIs

Oct 26, 2013 at 21:42 | Source: The Hindu BusinessLine

Over the last five years, Foreign Institutional Investors (FIIs) and retail investors have taken divergent views on Indian stocks. FIIs have steadily bought shares even as domestic institutions offloaded them. Foreign investors bought stocks worth R...

Natco hits peak on stake buy by CX Securities

Oct 22, 2013 at 05:12 | Source: Economic Times

MUMBAI: Shares of Hyderabad-based Natco Pharma scaled an all-time high on Monday after the drug maker informed the BSE that foreign institutional investor CX Securities has bought close to 7% stake in the company for Rs 153.22 crore. The stock gaine...

Natco to raise Rs 153 cr from CX Securities

Oct 20, 2013 at 22:52 | Source: The Hindu BusinessLine

The board of Natco Pharma Ltd on Saturday proposed to issue 24 lakh equity shares of Rs 10 each to CX Securities Ltd, a foreign institutional investor, on a preferential basis. In a release, the Hyderabad-based company said the shares will be issued...

Satish Reddy takes over as IPA chief

Oct 14, 2013 at 22:32 | Source: The Hindu BusinessLine

The Indian Pharmaceutical Alliance (IPA), representing large domestic drug-makers, has got a gen-next team as its helm. Satish Reddy, Vice Chairman and Managing Director of Dr Reddy’s Laboratories, has taken over as IPA President for 2013-15. ...

IPA gets a gen-next team at the helm

Oct 14, 2013 at 21:17 | Source: The Hindu BusinessLine

The Indian Pharmaceutical Alliance (IPA), representing large domestic drug-makers, has got a gen-next team as its helm. Satish Reddy, Vice Chairman and Managing Director of Dr Reddy’s Laboratories, has taken over as IPA President for 2013-15. ...

Natco Pharma plans to raise $24M to build syringe unit

Oct 04, 2013 at 18:00 | Source: VC Circle

Kotak Private Equity Group which invested Rs 23.7 crore in Natco two years ago part exited recently with 2x gains. Hyderabad-based Natco Pharma Ltd plans to raise around Rs 150 crore ($24.4 million) by the end of next month to build a pre-filled ...

Natco Pharma to raise Rs 150 crore for syringe unit

Oct 04, 2013 at 00:17 | Source: The Hindu BusinessLine

Natco Pharma Ltd will be raising about Rs 150 crore by end of next month to set up a pre-filled syringe unit. “We have obtained shareholders’ approval for mobilising up to Rs 300 crore, but we may need only Rs 150 crore at present,’...

Natco Pharma: There's little room for a major upside

Sep 25, 2013 at 13:37 | Source: Economic Times

One of the best performers in the pharma sector - the small-cap stock of Hyderabadbased Natco Pharma surged 64.5% in the past one year, closely trailing the 69% gains of the sector leader Sun Pharma whose promoter Dilip Shanghvi owns 3.67% in Natco P...

How small-cap funds did well

Sep 15, 2013 at 04:02 | Source: The Hindu BusinessLine

BSE small-cap index has plunged 17 per cent in the past one year, underperforming other indices by a wide margin. The BSE mid-cap index has tumbled only 9.5 per cent in this period, while bellwether indices Nifty and Sensex posted gains of 8 and 10 ...

Government refutes Novartis' allegations on patents

Aug 29, 2013 at 13:47 | Source: Economic Times

NEW DELHI: Tearing into the allegations made by Novartis on India's 'discriminatory' patent practices, the government has said global firms, including the Swiss drug major, have benefited more from the country's rules cornering over 80 per cent of th...

Govt refutes Novartis’ allegations on patents

Aug 28, 2013 at 20:42 | Source: The Hindu BusinessLine

Tearing into the allegations made by Novartis on India’s ‘discriminatory’ patent practices, the Government has said global firms, including the Swiss drug major, have benefited more from the country’s rules cornering over 80 ...

Novartis lashes out at India for not respecting Intellectual Property Rights

Aug 18, 2013 at 22:37 | Source: Financial Express

Hitting out at India's way of dealing with Intellectual Property Rights (IPR) issues, drug major Novartis has said India is losing investments in research and development from MNCs to China due to lack of an ecosystem that fosters innovation. Accord...

Roche gives up on India patent for breast cancer drug

Aug 16, 2013 at 18:00 | Source: VC Circle

Last year, India issued the first ever compulsory licence to domestic drugmaker Natco Pharma on a kidney and liver cancer drug, Nexavar, patented by Germany's Bayer. Roche Holding AG has decided not to pursue a patent application for its brea...

Swiss drug major Roche to drop anti-cancer drug Herceptin patent in India

Aug 16, 2013 at 15:07 | Source: Economic Times

MUMBAI: Swiss drug major Roche has decided not to pursue its patent for anti-cancer drug Herceptin, the patent which had come up for extension till 2019, paving the way for generic drug makers to manufacture this drug. Trastuzumab, sold under the bra...

Natco Pharma Q1 net profit up 28% at Rs 22 cr

Aug 14, 2013 at 19:32 | Source: The Hindu BusinessLine

Natco Pharma’s consolidated net profit increased 28 per cent at Rs 22 crore in the first quarter ended June 30 compared to Rs 17 crore in the same period last year. The revenue of the Hyderabad-based company grew by 21 per cent at Rs 182 crore...

1

video of the day

Mid-sized cos seeing order pickup; volatile Nifty: Ambit

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.